文献速递肝病

非酒精性脂肪性肝病中胰岛素抵抗的调控

Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Hepatology · 2019-07-19

综述指出非酒精性脂肪性肝病(NAFLD)在普通人群中患病率约25%,继发于非酒精性脂肪性肝炎(NASH)的肝硬化预计将成为肝移植的首要原因,但目前缺乏有效的获批治疗。胰岛素抵抗(IR)与NAFLD密切相关,糖尿病患者中NAFLD患病率较无糖尿病者高5倍,IR参与NAFLD发病及从脂肪变性向NASH进展,调控IR是潜在治疗策略。本文综述IR与NAFLD关联的关键机制及主要药物策略的疗效。

要点

  • NAFLD在普通人群中患病率约25%,糖尿病患者中NAFLD患病率较无糖尿病者高5倍。
  • IR参与NAFLD发病及从脂肪变性向NASH进展,调控IR是潜在治疗策略。
  • 综述讨论双胍类、GLP-1激动剂、DPP-4抑制剂、PPAR激动剂、SGLT2抑制剂及FXR激动剂的疗效。

核心结论

  • IR与NAFLD密切相关,调控IR是NAFLD的潜在治疗策略。
  • 理想的治疗应改善IR、降低心血管风险并产生可证明的NASH组织学改善,这很可能通过联合方案实现。

研究设计与样本

  • 综述,总结IR与NAFLD关联的机制及基于近期实验和临床数据的IR药物治疗策略疗效。

主要发现

  • NAFLD在普通人群中估计患病率约25%。
  • 糖尿病患者中NAFLD患病率较无糖尿病者高5倍。
  • IR参与NAFLD发病及从脂肪变性向NASH的进展。
  • IR与NAFLD关联的机制涉及脂肪组织脂解速率及从头脂肪生成变化、线粒体脂肪酸β氧化受损、脂肪分布改变、肠道微生物组改变及脂肪因子和细胞因子水平改变。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general population, and cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is predicted to become the leading cause of liver transplantation, yet there is a lack of effective licensed treatments for these conditions. There is a close relationship between insulin resistance (IR) and NAFLD, with prevalence of NAFLD being 5-fold higher in patients with diabetes compared to those without. IR is implicated both in pathogenesis of NAFLD and in disease progression from steatosis to NASH. Thus, modulation of IR represents a potential strategy for NAFLD treatment. This review highlights key proposed mechanisms linking IR and NAFLD, such as changes in rates of adipose tissue lipolysis and de novo lipogenesis, impaired mitochondrial fatty acid β-oxidation (FAO), changes in fat distribution, alterations in the gut microbiome, and alterations in levels of adipokines and cytokines. Furthermore, this review will discuss the main pharmacological strategies used to treat IR in patients with NAFLD and their efficacy based on recently published experimental and clinical data. These include biguanides, glucagon-like peptide 1 receptor (GLP-1) agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, peroxisome proliferator-activated receptor (PPAR-γ/α/δ) agonists, sodium glucose cotransporter 2 (SGLT2) inhibitors, and farnesoid X receptor (FXR) agonists, with further novel treatments on the horizon. Ideally, treatment would improve IR, reduce cardiovascular risk, and produce demonstrable improvements in NASH histology-this is likely to be achieved with a combinatorial approach.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Khan RS, Bril F, Cusi K, et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology. 2019. PMID: 30556145. doi:10.1002/hep.30429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。